Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement

JAMA. 2020 Feb 25;323(8):757-763. doi: 10.1001/jama.2020.0435.

Abstract

Importance: Dementia (also known as major neurocognitive disorder) is defined by a significant decline in 1 or more cognitive domains that interferes with a person's independence in daily activities. Dementia affects an estimated 2.4 to 5.5 million individuals in the United States, and its prevalence increases with age.

Objective: To update its 2014 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for cognitive impairment, including mild cognitive impairment and mild to moderate dementia, in community-dwelling adults, including those 65 years or older residing in independent living facilities.

Population: This recommendation applies to community-dwelling older adults 65 years or older, without recognized signs or symptoms of cognitive impairment.

Evidence assessment: The USPSTF concludes that the evidence is lacking, and the balance of benefits and harms of screening for cognitive impairment cannot be determined.

Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment in older adults. (I statement).

Publication types

  • Practice Guideline
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Cognitive Dysfunction / diagnosis*
  • Cognitive Dysfunction / therapy
  • Dementia / diagnosis*
  • Dementia / therapy
  • Early Diagnosis
  • Humans
  • Independent Living
  • Mass Screening* / adverse effects
  • Neuropsychological Tests
  • Sensitivity and Specificity